Pre-clinical Studies
Pillar objectives
Pillar 2 is dedicated to pre-clinical assessment of vaccine and antibody prototypes, including animal models (WP7), non-animal models (WP8) and immunomonitoring and immune profiling (WP9). Through a concerted effort by EVH partners, Pillar 2 aims to conceive and elaborate robust standardised protocols for pre-clinical analyses of vaccine and antibody candidates.
WP7 Pre-clinical animal models (Lead: DZIF; Partners involved: TiHO, ZEPAI, IP, CEA)
- Set relevant animal models for analysis of emerging and re-emerging infectious priority pathogens, also associated with outbreak scenarios
- Setup, evaluation and stress-testing of different animal models to test immunogenicity of vaccine and antibody prototypes using different immunization schedules
WP8 Pre-clinical non-animal models (Lead: IP)
- Establish non-animal models, in accordance with 3R principles of research (Replacement, Reduction, and Refinement), for the characterisation of preventive and therapeutic measures
- Use the innovative alternative “non-animals” approaches (organoids, organon-chip) to study pathophysiology of infection and to study impact of vaccine and antibody prototypes
WP9 Immuno-monitoring, immune profiling (Lead: IP; Partners involved: TiHO, ZEPAI, IZSVe)
- Develop and implement standardised laboratory tests to measure immune responses after pathogen infection or following immunization with vaccine and/or antibody candidates in diverse pre-clinical animal models
- Assess pre-clinical correlates of protection after pathogen challenge of immunised animals
• Led by Institut Pasteur (IP, France)
• Pillar 2 Leader: James Di Santo (IP)
• Pillar 2 Co-Leader: Asisa Volz (TiHo - Hannover, Germany)